GAL and Alzheimer disease: In vivo studies showed that IN-administered GAL that was encapsulated in PLGA-coated carbon nanoforms was successfully delivered to the hippocampus just a few hours after a single IN dose and shed light into the nanoparticle’s distribution in the distinct structural and functional hippocampal compartments that are differentially implicated in AD onset and progress.